Here are five key notes:
1. Fourth quarter revenue is expected to reach $35 million, flat compared to the same period last year.
2. The spinal fusion hardware products revenue is expected to reach $17 million while orthobiologics will be around $18 million, both flat compared to the same period last year.
3. The United States revenue is expected to increase 2 percent, hitting $31 million. The U.S. spinal fusion hardware revenue is expected to increase 1 percent and U.S. orthobiologics product revenue likely saw a 2 percent increase.
4. Full year revenue is expected to hit around $133.5 million with cash and cash equivalents around $33 million.
5. The expected 2016 full-year revenue will likely be around $136 million to $140 million, a 2 percent to 5 percent growth over the full year compared to 2015 revenue.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
